New hope for transplant patients battling debilitating immune reaction
NCT ID NCT05531786
Summary
This study is testing an oral drug called pacritinib for people with chronic graft-versus-host disease (cGVHD) that hasn't improved after at least two other treatments. cGVHD is a serious immune system complication that can occur after a stem cell transplant. The trial aims to see if pacritinib is safe and can help control the disease in up to 50 adults.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS. HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
-
University of Miami
RECRUITINGMiami, Florida, 33101, United States
Conditions
Explore the condition pages connected to this study.